A 47-year-old woman from Columbus comes in for a perimenopause workup. Hot flashes, sleep that fragments at 3 AM, brain fog, weight that has crept up despite no change in diet. She has been told twice in the last decade that her thyroid is "normal." When I pull her chart, the only thyroid marker that has ever been ordered is TSH, and it has been 2.8 to 3.4 across every draw. Inside the reference range. Never flagged.
I add free T3, free T4, reverse T3, and thyroid antibodies to her panel. Her TPO antibody comes back at 487 IU/mL. Her thyroglobulin antibody is also elevated. Her free T3 sits at the bottom 10% of the range. She has Hashimoto's, and she has had it for years, and nobody has told her — because TSH alone does not catch it.
That is the conversation I have more often than any other in my hormone practice. Hashimoto's thyroiditis and the hormonal transitions of mid-life do not run on parallel tracks. They feed each other, they amplify each other's symptoms, and a treatment plan for one that ignores the other will underperform.
Why TSH-only screening misses Hashimoto's for years
TSH is a pituitary hormone. It tells you what the pituitary thinks about thyroid output, not what is actually happening at the thyroid gland or at the tissue level. In early Hashimoto's, the gland is being slowly destroyed by an autoimmune process, but compensatory pituitary signaling can keep TSH inside the reference range for a decade or longer.
The markers that actually catch Hashimoto's early:
- TPO and thyroglobulin antibodies — these are the immunological signature of the disease itself
- Free T3 and free T4 — the active and storage forms of thyroid hormone, measured at the tissue level
- Reverse T3 — an inactive form that competes with free T3 at the receptor; elevated in stress states and in poorly converted thyroid pictures
When I evaluate a mid-life woman with the symptom cluster that brings her into my office, I run all of those at the first draw. About one in four mid-life women I work up with this presentation has previously undiagnosed Hashimoto's, and it changes everything about how I approach her hormone optimization.
How Hashimoto's interacts with sex hormone decline
The thyroid axis and the sex hormone axis are not separate systems. They share regulatory machinery, they share peripheral conversion enzymes, and they share signaling sensitivity at the tissue level. In the practical clinical picture, that means three things happen when a woman with Hashimoto's enters perimenopause:
The symptom burden is heavier. Both declining estradiol and suboptimal thyroid produce fatigue, weight gain, cognitive sluggishness, and mood instability. When both are running, the symptoms are not additive — they are amplified. A patient whose estradiol drop alone would have produced moderate symptoms ends up with severe symptoms because her thyroid was never optimized to begin with.
Progesterone deficiency aggravates the autoimmune picture. Progesterone has immunomodulatory effects. As progesterone declines through perimenopause, the autoimmune inflammation can intensify, and antibody titers can rise. I have watched patients' TPO antibodies climb steadily across their 40s while their symptoms worsened in parallel.
Estrogen replacement, if delivered through the wrong route, raises SHBG and binding proteins that affect thyroid hormone availability. Oral estrogen in particular increases thyroxine-binding globulin, which can functionally lower free T3 and T4 even when total thyroid levels look adequate. A patient on oral estrogen plus levothyroxine can end up clinically hypothyroid despite "normal" labs because the binding picture has shifted.
This is why I do not treat Hashimoto's and hormone optimization as two separate conversations. They have to be planned together.
How I evaluate a patient who has both
When a perimenopausal or menopausal woman with confirmed or suspected Hashimoto's comes in for hormone optimization, the workup expands to include the full thyroid picture. The questions I am answering before I write any plan:
- Is the thyroid currently optimized? Free T3 in the upper third of the range, reverse T3 not elevated, TSH usually 0.5 to 2.0 in a treated patient.
- What is the antibody titer doing? Stable, rising, falling? Rising titers suggest active flare.
- What is the sex hormone picture? Estradiol, progesterone, total and free testosterone, SHBG, DHEA-S.
- What is the metabolic picture? Insulin, HbA1c, lipid panel — Hashimoto's patients have higher rates of insulin resistance.
- What is the inflammatory picture? hs-CRP, ferritin (which doubles as iron status and an inflammation marker).
- Are there nutritional cofactors that need attention? Vitamin D, B12, selenium, ferritin.
I order comprehensive lab work at the first visit if the patient does not already have recent results, and we sit with the data together at the second visit. The treatment plan is built from what the data shows, not from a default template.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
What treatment looks like when both are on the table
A few principles guide how I sequence this:
Optimize thyroid first or in parallel — never after. Starting estrogen replacement in a patient with untreated Hashimoto's whose free T3 is at the bottom of the range is a recipe for the patient feeling worse before she feels better. The thyroid picture has to be addressed.
Choose delivery routes that minimize binding-protein interference. I prefer transdermal estradiol over oral in patients with thyroid disease. Same dose, far less impact on TBG and SHBG. For some patients Biote pellet therapy is the cleanest delivery route — steady-state hormone without oral first-pass effects, and the dosing is calibrated to her specific labs rather than to a manufacturer's tablet strength.
Include progesterone for its immunomodulatory effect, not just for endometrial protection. In a Hashimoto's patient, progesterone is not optional just because she has had a hysterectomy. The systemic effect on inflammation and on the autoimmune process is part of why I include it.
Monitor thyroid markers more frequently after starting estrogen. Standard reassessment is at three months. In a Hashimoto's patient I often check thyroid at six weeks after any estrogen dose change, because the binding-protein shifts can move free hormone availability faster than the symptom picture reflects.
Address the autoimmune drivers, not just the hormone levels. Vitamin D optimization to a 25-OH level of 50 to 80 ng/mL. Selenium 200 mcg daily — there is reasonable evidence it lowers TPO antibody titers in some patients. Gluten reduction in patients with concurrent gut symptoms or elevated zonulin. Sleep, stress, and inflammation all matter.
What I look for at follow-up
At the first reassessment — usually twelve weeks after initiating any change — I am looking at three things in parallel:
The labs. Free T3 in the upper third, reverse T3 not climbing, estradiol and progesterone in the optimization range for her stage of life, antibody titers stable or trending down.
The symptom inventory. Energy, sleep depth, cognitive clarity, mood, body composition trajectory. I track these explicitly because patient memory of how they felt three months ago is unreliable, and the comparison only works if we have a baseline document.
The integration. Is the plan she is on actually sustainable? A protocol that produces good labs but that the patient cannot maintain is a failed protocol. Sometimes a slightly less aggressive plan that the patient will actually follow produces better long-term outcomes than the textbook ideal.
If something is off — symptoms persisting, antibodies rising, free T3 not coming up — I do not double down on the same plan. I look for what we missed. Common culprits at the three-month visit: insufficient T3 conversion (often a selenium or zinc gap), persistent inflammation from a gut driver, sleep architecture problems that are limiting hormone signaling, or a binding-protein shift from a delivery route that needs adjustment.
What I do not do
I do not treat thyroid antibodies in isolation. A patient whose antibodies are positive but whose free T3 and free T4 are optimal and who feels well does not need pharmacological intervention — she needs annual monitoring and attention to the inflammatory cofactors.
I do not start someone on T3-only protocols without a clear clinical reason. T3 has its place, but it has a narrow therapeutic window and requires careful monitoring. The patient who feels better on T3-only sometimes feels better because she is mildly hyperthyroid, and that is not a sustainable position.
I do not assume a patient who was diagnosed with Hashimoto's in her 30s and put on levothyroxine is currently optimized. The dose she needs at 47 is rarely the dose she needed at 33. I have seen patients on 50 mcg of levothyroxine for fifteen years whose free T3 has been in the bottom 5% of range the whole time. That is not treatment. That is documented hypothyroidism with a prescription on file.
Concrete next step
If you are a woman in middle Georgia with diagnosed Hashimoto's who is now in perimenopause, or if you have the symptom cluster of perimenopause and have only ever had a TSH ordered — bring me the panel itself. Not just the summary. If your last full thyroid panel was more than twelve months ago and did not include free T3, reverse T3, and antibodies, I will order it at the first visit along with the sex hormone and metabolic panels. We sit with the data at visit two and build a plan that addresses both axes together. Book a consultation at the Columbus location or the Warner Robins location and mention thyroid history at intake so the lab order goes in correctly the first time.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.